<DOC>
	<DOCNO>NCT00867529</DOCNO>
	<brief_summary>This phase II trial study give rituximab donor peripheral blood stem cell transplant patient B-cell lymphoma respond treatment ( refractory ) come back period improvement ( relapse ) . Monoclonal antibody , rituximab , interfere ability cancer cell grow spread . Giving rituximab donor peripheral blood stem cell transplant may help stop cancer come back may help keep patient 's immune system reject donor 's stem cell .</brief_summary>
	<brief_title>Rituximab Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant Relapsed Refractory B-cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine effect addition peri-transplant rituximab relapse rate 18 month non-myeloablative allogeneic hematopoietic cell transplant ( HCT ) cluster differentiation ( CD ) 20+ B-cell malignancy . SECONDARY OBJECTIVES : I . To determine overall progression-free survival non-relapse mortality . II . To determine incidence severity acute chronic graft-versus-host disease ( GVHD ) . III . To determine rate graft rejection graft failure . IV . To determine time engraftment . V. To determine incidence serious adverse event addition rituximab . VI . To evaluate pharmacokinetics rituximab set non-myeloablative allogeneic HCT . VII . To describe donor host polymorphism FC gamma receptor IIIa ( FCg RIIIA ) CD32 evaluate impact disease response relapse . OUTLINE : Patients receive rituximab intravenously ( IV ) , pre- post-transplant , day -3 , 10 , 24 , 38 . Patients undergo donor peripheral blood stem cell transplant day 0 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 18 month annually 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>With diagnosis CD20expressing Bcell malignancy histologic type grade nonmyeloablative allogeneic transplant consider appropriate treatment option Who enrol nonmyeloablative allogeneic HCT protocol employ totalbody irradiation ( TBI ) base condition = &lt; 4.5 Gy , without fludarabine ; protocol may use adjunct allogeneic arm tandem autologous/allogeneic transplant protocol , provide allogeneic condition meet criterion Receiving unmodified peripheral blood mononuclear cell graft product With appropriate relate unrelated donor ; human leukocyte antigen ( HLA ) haploidentical donor exclude Able give inform consent ( &gt; = 18 year age ) , legal guardian capable give consent ( &lt; 18 year age ) Ineligible nonmyeloablative allogeneic HCT Receiving HLAhaploidentical allograft Who fertile unwilling use contraception least 12 month HCT Females pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>